Treatment discontinuation · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
It is very uncertain whether injectional interferon alpha‐2B changes discontinuation from treatment compared with saline (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with chronic Peyronie's disease (plaques without calcification)
It is very uncertain whether injectional nicardipine changes discontinuation from treatment compared with saline (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with Peyronie's disease (not defined)
1 finding from 1 review
Treatment discontinuation · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)
The review found no eligible studies for this question.
2 findings from 1 review
Treatment discontinuation · men with Peyronie's disease (palpable plaque or pain)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · men with Peyronie's disease (palpable plaque or pain)
It is very uncertain whether extracorporeal shock wave treatment (ESWT) changes discontinuation from treatment compared with sham (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…
It is very uncertain whether potassium paraaminobenzoate changes discontinuation from treatment compared with placebo (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
It is very uncertain whether penile traction therapy changes discontinuation from treatment compared with no treatment (short‐term) (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in discontinuation due to adverse events Range of compared with any first‐line chemotherapy (low certainty).
1 finding from 1 review
Intervention not reported
Time to initiation of first subsequent therapy This outcome was not reported as a time‐to‐event outcome. Instead, authors of the trials reported the number of participants who received subsequent anticancer therapy after discontinuation of trial t... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention may leads to lower time to initiation of first subsequent therapy This outcome was not… (low certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (long‐term)
Scheduled PDE5I showed no clear difference in treatment discontinuation compared with on demand placebo or no treatment (moderate certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
Scheduled PDE5I showed no clear difference in treatment discontinuation compared with on demand PDE5I (low certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (long‐term)
It is very uncertain whether scheduled PDE5I changes treatment discontinuation compared with on demand PDE5I (very low certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes treatment discontinuation compared with on demand placebo or no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
1 finding from 1 review
Discontinuation of therapy due to adverse events ‐ not measured · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found